Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

Organon is making good on its promise to investors that it will build out its women's health portfolio. The company announced its first licensing deal on 27 July, in its second month after spinning out from Merck & Co. Organon bought worldwide licensing rights to ebopiprant for acute preterm labor in a deal with Swiss women's health specialist ObsEva SA.

Ebopiprant is a potential first-in-class selective prostaglandin F2α (PGF2α) receptor antagonist that could treat preterm labor by reducing inflammation and uterine contractions. There are currently no approved therapies for acute...